^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

Published date:
02/08/2022
Excerpt:
Case 1 is a 33-year-old female diagnosed with AML...t(8;21)(q22;q22)...KIT exon 17 and CSF3R mutations were detected...KIT exon 17 and CSF3R mutations were detected...This patient then received venetoclax+AZA for one cycle. After the treatment, the BM revealed 75% blasts, and the patient presented with symptoms of fatigue, lassitude and bone pain, which suggested disease progression.
Secondary therapy:
azacitidine
DOI:
https://doi.org/10.3389/fonc.2022.841276